OncoMatch/Lung Cancer — Small Cell (SCLC)/BRCA1
Lung Cancer — Small Cell (SCLC)BRCA1 Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
BRCA1 alterations occur in approximately 5–8% of SCLC and may confer sensitivity to PARP inhibition given SCLC's inherently high genomic instability and reliance on homologous recombination repair. Olaparib and veliparib have been explored in biomarker-enriched SCLC cohorts. Trials investigate PARP inhibitor combinations with platinum chemotherapy or immunotherapy specifically in BRCA1/2-altered or HRD-positive SCLC.
Top recruiting
Top recruiting BRCA1 Lung Cancer — Small Cell (SCLC) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Lung Cancer — Small Cell (SCLC) biomarkers
Browse other molecular targets with active Lung Cancer — Small Cell (SCLC) trials.